Senti Biosciences Holdings (SNTI) Change in Accured Expenses (2021 - 2025)

Senti Biosciences Holdings' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $251000.0 for Q4 2025.

• In Q4 2025, Change in Accured Expenses fell 87.64% year-over-year to $251000.0; the TTM figure through Dec 2025 stood at $559000.0 (up 183.31% YoY), while the FY2025 annual figure was $559000.0, up 183.31% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $251000.0, down from $1.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.1 million in Q4 2021, with the low at -$2.9 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $142206.0 (2021), against an average of $288730.4.
• Peak annual rise in Change in Accured Expenses reached 68753.86% in 2022, while the deepest fall reached 137551.36% in 2022.
• Senti Biosciences Holdings' Change in Accured Expenses stood at $3.1 million in 2021, then sank by 81.58% to $567000.0 in 2022, then jumped by 237.04% to $1.9 million in 2023, then rose by 6.28% to $2.0 million in 2024, then slumped by 87.64% to $251000.0 in 2025.
• Business Quant data shows SNTI's Change in Accured Expenses at $251000.0 in Q4 2025, $1.5 million in Q3 2025, and -$48000.0 in Q2 2025.